

# Differences in glucose production, lipolysis and proteolysis during different BASal INsulins, in patients with type two diabetes

<b>Submission date</b> 30/05/2007	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 30/05/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 19/10/2021	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr M.R. Soeters

**Contact details**  
Academic Medical Centre (AMC)  
Department of Endocrinology & Metabolism, F5-162  
P.O. Box 22660  
Amsterdam  
Netherlands  
1100 DD  
+31 (0)20 5667672 / 5669111  
M.R.Soeters@amc.uva.nl

## Additional identifiers

**Protocol serial number**  
NL926 (NTR950)

## Study information

**Scientific Title**

Differences in glucose production, lipolysis and proteolysis during different BASal INSulins, in patients with type two diabetes

## **Acronym**

BASIN

## **Study objectives**

Differences exist in duration of effect of insulin detemir, insulin glargine or Neutral Protamine Hagedorn (NPH) insulin on glucose production, lipolysis and proteolysis in patients with type two diabetes mellitus.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Ethics approval received from the local medical ethics committee

## **Study design**

Randomised, active controlled, parallel group, multicentre trial

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Diabetes Mellitus type 2 (DM type II)

## **Interventions**

The patients are admitted to the metabolic unit of the Academic Medical Centre at 4.30 pm, with the last meal and usual insulin dosage of short-acting insulin taken at 12.00 am. The long-acting insulin is injected in the subcutis of the thigh at bedtime. Measurements of Hepatic Glucose Production (HGP), lipolysis and proteolysis will start one hour after the administration of the basal insulin at bedtime.

## **Intervention Type**

Drug

## **Phase**

Not Specified

## **Drug/device/biological/vaccine name(s)**

Insulin

## **Primary outcome(s)**

1. Hepatic Glucose Production (HGP)
2. Lipolysis
3. Proteolysis

## **Key secondary outcome(s))**

1. Plasma Glucose
2. Free fatty acids levels

**Completion date**

01/08/2008

## Eligibility

**Key inclusion criteria**

1. Caucasian male patients with Diabetes Mellitus Type Two (DM II)
2. Basal bolus insulin therapy with NPH, detemir or glargine for at least one year
3. Basal insulin dosage:  $30 \pm 10$  U
4. Fasting plasma glucose: 7.5 - 10.0 mmol/l
5. HbA1c 7.5 - 9%
6. Age 40 to 65 years
7. Body Mass Index (BMI) 26 - 30 kg/m<sup>2</sup>

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

Male

**Key exclusion criteria**

1. Major flaws in injection technique, as indicated by subcutaneous infiltration
2. Creatinine greater than 100  $\mu$ mol/L or diabetic nephropathy
3. Abnormal liver enzymes (greater than 2 x upper limit of normal) and fasting triglycerides greater than 3 mmol/L
4. Clinically manifest autonomic neuropathy
5. Macrovascular complications of DM II, except for peripheral arterial disease
6. Epilepsy
7. Drugs interfering with insulin sensitivity and lipolysis, other than metformin
8. Alcohol abuse (greater than 5/day)
9. Fever/infection
10. Dietary fat content greater than 75%

**Date of first enrolment**

01/08/2007

**Date of final enrolment**

01/08/2008

## Locations

**Countries of recruitment**

Netherlands

**Study participating centre**

**Academic Medical Centre (AMC)**

Amsterdam

Netherlands

1100 DD

## Sponsor information

**Organisation**

Academic Medical Centre (AMC) (The Netherlands)

**ROR**

<https://ror.org/03t4gr691>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Novo Nordisk (Denmark)

**Alternative Name(s)**

Novo Nordisk Global

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

For-profit companies (industry)

**Location**

Denmark

## Results and Publications

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**  
Not provided at time of registration